Enanta Pharmaceuticals unveils new RSV and STAT6 data at American Thoracic Society conference

Enanta Pharmaceuticals unveils new RSV and STAT6 data at American Thoracic Society conference
Enanta reveals RSV, STAT6 data

Enanta Pharmaceuticals presented new research findings on its RSV and STAT6 programs at the American Thoracic Society International Conference held in Orlando, Florida.

Team members shared data and insights aimed at advancing treatments for respiratory diseases, with conference materials highlighting the company’s ongoing commitment to medical innovation. Full presentations are available online through the event’s official channels.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.